1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Wu, Y. Wang, J. DeGrado, W. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic C18 H23 N2 O S 1 315.453 (3S,5S,7S)-N-{[5-(thiophen-2-yl)-1,2-oxazol-3-yl]methyl}tricyclo[3.3.1.1~3,7~]decan-1-aminium non-polymer C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US Proc.Natl.Acad.Sci.USA PNASA6 0040 0027-8424 110 1315 1320 10.1073/pnas.1216526110 23302696 Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus. 2013 10.2210/pdb2ly0/pdb pdb_00002ly0 3497.116 Membrane ion channel M2 C19S 4 syn polymer 315.453 (3S,5S,7S)-N-{[5-(thiophen-2-yl)-1,2-oxazol-3-yl]methyl}tricyclo[3.3.1.1~3,7~]decan-1-aminium 1 syn non-polymer no no SNDSSDPLVVAANIIGILHLILWILDRLFFK SNDSSDPLVVAANIIGILHLILWILDRLFFK A,B,C,D polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n database_2 pdbx_database_status pdbx_nmr_software pdbx_nmr_spectrometer struct_site repository Initial release Database references Database references Data collection Database references Derived calculations Other 1 0 2013-01-09 1 1 2013-01-23 1 2 2013-02-06 1 3 2023-06-14 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_database_status.status_code_nmr_data _pdbx_nmr_software.name _pdbx_nmr_spectrometer.model _struct_site.pdbx_auth_asym_id _struct_site.pdbx_auth_comp_id _struct_site.pdbx_auth_seq_id BMRB Y RCSB 2012-09-10 REL REL REL REL A2Y (3S,5S,7S)-N-{[5-(thiophen-2-yl)-1,2-oxazol-3-yl]methyl}tricyclo[3.3.1.1~3,7~]decan-1-aminium 221020 Influenza A virus sample AUTHORS STATE THAT THIS IS A DRUG-RESISTANT MUTANT. structures with the lowest energy 100 20 2D 1H-15N HSQC 3D HNCO 3D HNCA 3D HNCACB 3D 1H-15N NOESY 3D 1H-13C NOESY 3D 1H-13C NOESY 3D 1H-13C NOESY 2D 1H-13C HSQC 3D CCH_TOCSY 2 mM [U-100% 15N] 2 mM [U-100% 13C; U-100% 15N] 2 mM [U-100% 13C; U-100% 15N; U-80% 2H] 2 mM [U-10% 13C; U-100% 15N] 2 mM mixature of 50% 13C15N and 50% 12C14N 2 mM 13C15N of V27A30N31I33G34 0.05 6.8 ambient 313 K simulated annealing 1 lowest energy 2 mM mM [U-100% 15N] protein, 90% H2O/10% D2O 90% H2O/10% D2O 2 mM mM [U-100% 13C; U-100% 15N] protein, 90% H2O/10% D2O 90% H2O/10% D2O 2 mM mM [U-100% 13C; U-100% 15N; U-80% 2H] protein, 90% H2O/10% D2O 90% H2O/10% D2O 2 mM mM [U-10% 13C; U-100% 15N] protein, 90% H2O/10% D2O 90% H2O/10% D2O 2mM mM mixature of 50% 13C15N and 50% 12C14N protein, 90% H2O/10% D2O 90% H2O/10% D2O 2mM mM 13C15N of V27A30N31I33G34 protein, 90% H2O/10% D2O 90% H2O/10% D2O Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax processing NMRPipe Bartels et al. chemical shift assignment XEASY Bartels et al. peak picking XEASY Schwieters, Kuszewski, Tjandra and Clore structure solution X-PLOR NIH Schwieters, Kuszewski, Tjandra and Clore refinement X-PLOR NIH 900 Bruker AVANCE Bruker Avance 800 Bruker AVANCE Bruker Avance A2Y 100 2 A2Y A2Y 100 A SER 19 n 1 SER 19 A ASN 20 n 2 ASN 20 A ASP 21 n 3 ASP 21 A SER 22 n 4 SER 22 A SER 23 n 5 SER 23 A ASP 24 n 6 ASP 24 A PRO 25 n 7 PRO 25 A LEU 26 n 8 LEU 26 A VAL 27 n 9 VAL 27 A VAL 28 n 10 VAL 28 A ALA 29 n 11 ALA 29 A ALA 30 n 12 ALA 30 A ASN 31 n 13 ASN 31 A ILE 32 n 14 ILE 32 A ILE 33 n 15 ILE 33 A GLY 34 n 16 GLY 34 A ILE 35 n 17 ILE 35 A LEU 36 n 18 LEU 36 A HIS 37 n 19 HIS 37 A LEU 38 n 20 LEU 38 A ILE 39 n 21 ILE 39 A LEU 40 n 22 LEU 40 A TRP 41 n 23 TRP 41 A ILE 42 n 24 ILE 42 A LEU 43 n 25 LEU 43 A ASP 44 n 26 ASP 44 A ARG 45 n 27 ARG 45 A LEU 46 n 28 LEU 46 A PHE 47 n 29 PHE 47 A PHE 48 n 30 PHE 48 A LYS 49 n 31 LYS 49 A SER 19 n 1 SER 19 B ASN 20 n 2 ASN 20 B ASP 21 n 3 ASP 21 B SER 22 n 4 SER 22 B SER 23 n 5 SER 23 B ASP 24 n 6 ASP 24 B PRO 25 n 7 PRO 25 B LEU 26 n 8 LEU 26 B VAL 27 n 9 VAL 27 B VAL 28 n 10 VAL 28 B ALA 29 n 11 ALA 29 B ALA 30 n 12 ALA 30 B ASN 31 n 13 ASN 31 B ILE 32 n 14 ILE 32 B ILE 33 n 15 ILE 33 B GLY 34 n 16 GLY 34 B ILE 35 n 17 ILE 35 B LEU 36 n 18 LEU 36 B HIS 37 n 19 HIS 37 B LEU 38 n 20 LEU 38 B ILE 39 n 21 ILE 39 B LEU 40 n 22 LEU 40 B TRP 41 n 23 TRP 41 B ILE 42 n 24 ILE 42 B LEU 43 n 25 LEU 43 B ASP 44 n 26 ASP 44 B ARG 45 n 27 ARG 45 B LEU 46 n 28 LEU 46 B PHE 47 n 29 PHE 47 B PHE 48 n 30 PHE 48 B LYS 49 n 31 LYS 49 B SER 19 n 1 SER 19 C ASN 20 n 2 ASN 20 C ASP 21 n 3 ASP 21 C SER 22 n 4 SER 22 C SER 23 n 5 SER 23 C ASP 24 n 6 ASP 24 C PRO 25 n 7 PRO 25 C LEU 26 n 8 LEU 26 C VAL 27 n 9 VAL 27 C VAL 28 n 10 VAL 28 C ALA 29 n 11 ALA 29 C ALA 30 n 12 ALA 30 C ASN 31 n 13 ASN 31 C ILE 32 n 14 ILE 32 C ILE 33 n 15 ILE 33 C GLY 34 n 16 GLY 34 C ILE 35 n 17 ILE 35 C LEU 36 n 18 LEU 36 C HIS 37 n 19 HIS 37 C LEU 38 n 20 LEU 38 C ILE 39 n 21 ILE 39 C LEU 40 n 22 LEU 40 C TRP 41 n 23 TRP 41 C ILE 42 n 24 ILE 42 C LEU 43 n 25 LEU 43 C ASP 44 n 26 ASP 44 C ARG 45 n 27 ARG 45 C LEU 46 n 28 LEU 46 C PHE 47 n 29 PHE 47 C PHE 48 n 30 PHE 48 C LYS 49 n 31 LYS 49 C SER 19 n 1 SER 19 D ASN 20 n 2 ASN 20 D ASP 21 n 3 ASP 21 D SER 22 n 4 SER 22 D SER 23 n 5 SER 23 D ASP 24 n 6 ASP 24 D PRO 25 n 7 PRO 25 D LEU 26 n 8 LEU 26 D VAL 27 n 9 VAL 27 D VAL 28 n 10 VAL 28 D ALA 29 n 11 ALA 29 D ALA 30 n 12 ALA 30 D ASN 31 n 13 ASN 31 D ILE 32 n 14 ILE 32 D ILE 33 n 15 ILE 33 D GLY 34 n 16 GLY 34 D ILE 35 n 17 ILE 35 D LEU 36 n 18 LEU 36 D HIS 37 n 19 HIS 37 D LEU 38 n 20 LEU 38 D ILE 39 n 21 ILE 39 D LEU 40 n 22 LEU 40 D TRP 41 n 23 TRP 41 D ILE 42 n 24 ILE 42 D LEU 43 n 25 LEU 43 D ASP 44 n 26 ASP 44 D ARG 45 n 27 ARG 45 D LEU 46 n 28 LEU 46 D PHE 47 n 29 PHE 47 D PHE 48 n 30 PHE 48 D LYS 49 n 31 LYS 49 D author_defined_assembly 4 tetrameric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 1 A PHE 48 -45.14 162.29 1 B PHE 48 -45.19 162.38 1 C PHE 48 -45.20 162.34 1 D PHE 48 -45.29 162.37 5 A PHE 47 -93.64 40.62 5 A PHE 48 -45.84 173.82 5 B PHE 47 -93.61 40.69 5 B PHE 48 -45.85 173.82 5 C PHE 47 -93.54 40.62 5 C PHE 48 -46.01 173.81 5 D PHE 47 -93.55 40.68 5 D PHE 48 -46.06 173.93 6 A PHE 47 -92.56 40.50 6 B PHE 47 -92.58 40.55 6 C PHE 47 -92.59 40.67 6 D PHE 47 -92.72 40.68 7 A PHE 48 -155.58 66.02 7 B PHE 48 -155.69 66.46 7 C PHE 48 -155.63 66.42 7 D PHE 48 -155.52 66.54 8 A SER 23 -149.12 -143.80 8 B SER 23 -149.28 -143.76 8 C SER 23 -149.18 -143.79 8 D SER 23 -149.20 -143.75 9 A PHE 47 -101.26 40.71 9 A PHE 48 -45.71 86.47 9 B PHE 47 -101.02 40.81 9 B PHE 48 -45.83 86.58 9 C PHE 47 -101.45 40.88 9 C PHE 48 -45.81 86.21 9 D PHE 47 -101.27 40.79 9 D PHE 48 -45.92 86.47 11 A ASP 24 -49.42 151.59 11 B ASP 24 -49.40 151.25 11 C ASP 24 -49.30 151.47 11 D ASP 24 -49.79 151.04 13 A PHE 47 -68.90 -72.41 13 B PHE 47 -68.72 -72.52 13 C PHE 47 -68.89 -72.45 13 D PHE 47 -68.82 -72.44 15 A SER 23 -75.89 -136.41 15 A PHE 48 -155.16 83.55 15 B SER 23 -76.00 -136.46 15 B PHE 48 -155.09 83.54 15 C SER 23 -75.81 -136.54 15 C PHE 48 -155.10 83.51 15 D SER 23 -75.86 -136.39 15 D PHE 48 -155.06 83.69 18 A PHE 48 -156.90 70.71 18 B PHE 48 -156.89 70.92 18 C PHE 48 -156.93 70.90 18 D PHE 48 -156.84 70.76 19 A SER 23 38.64 93.58 19 B SER 23 38.52 93.66 19 C SER 23 38.65 93.48 19 D SER 23 38.55 93.73 Solution NMR structure of the influenza A virus S31N mutant (19-49) in presence of drug M2WJ332 1 N N 1 N N 1 N N 1 N N 2 N N A ASP 24 A ASP 6 HELX_P A PHE 47 A PHE 29 1 1 24 B ASP 24 B ASP 6 HELX_P B PHE 47 B PHE 29 1 2 24 C ASP 24 C ASP 6 HELX_P C PHE 47 C PHE 29 1 3 24 D ASP 24 D ASP 6 HELX_P D PHE 47 D PHE 29 1 4 24 VIRAL PROTEIN influenza A virus, M2 channel, S31N inhibitor, VIRAL PROTEIN Q6XT21_9INFA UNP 1 19 Q6XT21 CNDSSDPLVVAANIIGILHLILWILDRLFFK 19 49 2LY0 19 49 Q6XT21 A 1 1 31 19 49 2LY0 19 49 Q6XT21 B 1 1 31 19 49 2LY0 19 49 Q6XT21 C 1 1 31 19 49 2LY0 19 49 Q6XT21 D 1 1 31 1 CYS SEE REMARK 999 SER 19 2LY0 A Q6XT21 UNP 19 1 2 CYS SEE REMARK 999 SER 19 2LY0 B Q6XT21 UNP 19 1 3 CYS SEE REMARK 999 SER 19 2LY0 C Q6XT21 UNP 19 1 4 CYS SEE REMARK 999 SER 19 2LY0 D Q6XT21 UNP 19 1 BINDING SITE FOR RESIDUE A2Y A 100 A A2Y 100 Software 5 A VAL 27 A VAL 9 5 1_555 A ALA 30 A ALA 12 5 1_555 B VAL 27 B VAL 9 5 1_555 C VAL 27 C VAL 9 5 1_555 D VAL 27 D VAL 9 5 1_555